argenx to Acquire Forte Biosciences for $2.2B, Adding First-in-Class Anti-CD122 Antibody FB102
ARGX sits 63% above its 52-week low of $577.04.
Summary
argenx will acquire Forte Biosciences for $2.2 billion in cash, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, to its immunology pipeline.
Key Events · M&A and Partnerships · ARGX
-
Acquisition of Forte Biosciences
argenx to acquire Forte Biosciences for $77 per share in cash, a total equity value of approximately $2.2 billion, representing an 86% premium to Forte's VWAP since reporting positive Phase 1b vitiligo data.
-
FB102 Pipeline Addition
FB102 is a first-in-class anti-CD122 antibody with positive Phase 1b data in vitiligo and celiac disease, and potential in alopecia areata and other autoimmune diseases, complementing argenx's existing FcRn and complement-targeting franchises.
-
Financial Impact
The all-cash transaction will be funded from argenx's $5.2 billion cash reserves, avoiding dilution; the $2.2 billion price tag is a significant but manageable outlay for a company with a $57 billion market cap.
-
Strategic Rationale
The deal aligns with argenx's Vision 2030 strategy to build a leading immunology portfolio, adding a novel mechanism (CD122) that targets pathogenic T-cell and NK-cell activity, distinct from its current antibody programs.
Analysis · ARGX · Life Sciences
argenx is acquiring Forte Biosciences for $2.2 billion in cash, gaining FB102, a first-in-class anti-CD122 antibody with positive Phase 1b data in vitiligo and celiac disease. The deal adds a novel mechanism targeting pathogenic T-cell and NK-cell activity to argenx's immunology portfolio, complementing its existing FcRn blocker VYVGART. The 86% premium to Forte's recent VWAP reflects confidence in FB102's pipeline-in-a-product potential across multiple autoimmune diseases. Funded entirely from argenx's $5.2 billion cash pile, the transaction is not dilutive to shareholders and is expected to close in Q3 2026. This acquisition strengthens argenx's long-term growth prospects beyond its current blockbuster franchise.
At the time of this filing, ARGX was trading at $939.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $57.2B. The 52-week trading range was $577.04 to $953.58. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.